NO20002149L - Procedure for reducing mammalian addiction - Google Patents

Procedure for reducing mammalian addiction

Info

Publication number
NO20002149L
NO20002149L NO20002149A NO20002149A NO20002149L NO 20002149 L NO20002149 L NO 20002149L NO 20002149 A NO20002149 A NO 20002149A NO 20002149 A NO20002149 A NO 20002149A NO 20002149 L NO20002149 L NO 20002149L
Authority
NO
Norway
Prior art keywords
addiction
procedure
reducing mammalian
mammal
reducing
Prior art date
Application number
NO20002149A
Other languages
Norwegian (no)
Other versions
NO20002149D0 (en
Inventor
Vicki Coffin
Paul Glue
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO20002149D0 publication Critical patent/NO20002149D0/en
Publication of NO20002149L publication Critical patent/NO20002149L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Fremgangsmåte for å redusere avhengighet hos et pattedyr til mat eller en vanedannende substans beskrives. Fremgangsmåten omfatter administrering til pattedyret av en effektiv mengde av en D|/D5- antagonist eller en partiell Dt/Dj-agonist alene eller i kombinasjon med andre spesifikke CNS-forbindelser.Methods for reducing addiction in a mammal to food or an addictive substance are described. The method comprises administering to the mammal an effective amount of a D1 / D5 antagonist or a partial Dt / D1 agonist alone or in combination with other specific CNS compounds.

NO20002149A 1997-10-28 2000-04-27 Procedure for reducing mammalian addiction NO20002149L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95921397A 1997-10-28 1997-10-28
PCT/US1998/022255 WO1999021540A2 (en) 1997-10-28 1998-10-26 Method of reducing craving in mammals

Publications (2)

Publication Number Publication Date
NO20002149D0 NO20002149D0 (en) 2000-04-27
NO20002149L true NO20002149L (en) 2000-06-26

Family

ID=25501785

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20002149A NO20002149L (en) 1997-10-28 2000-04-27 Procedure for reducing mammalian addiction

Country Status (16)

Country Link
EP (1) EP1043980A2 (en)
JP (1) JP2001520989A (en)
KR (1) KR20010031470A (en)
CN (1) CN1283116A (en)
AR (1) AR015984A1 (en)
AU (1) AU1110099A (en)
BR (1) BR9814830A (en)
CA (1) CA2308453A1 (en)
CO (1) CO4970824A1 (en)
HU (1) HUP0100115A2 (en)
IL (1) IL135659A0 (en)
NO (1) NO20002149L (en)
PE (1) PE122299A1 (en)
SK (1) SK5812000A3 (en)
WO (1) WO1999021540A2 (en)
ZA (1) ZA989786B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410527B1 (en) * 1998-03-02 2002-06-25 Schering Corporation Method of treating obsessive compulsive disorders, somatoform disorders, dissociative disorders, eating disorders, impulse control disorders, and autism
PE20000333A1 (en) * 1998-03-02 2000-05-13 Schering Corp METHOD TO TREAT OBSESSIVE COMPULSIVE DISORDERS, SOMATOFORM DISORDERS, DISSOCIATIVE DISORDERS, EATING DISORDERS, IMPULSE CONTROL DISORDERS AND AUTISM
US6890951B2 (en) 1998-08-05 2005-05-10 Brookhaven Science Associates Llc Treatment of addiction and addiction-related behavior
US6541520B1 (en) 1998-08-05 2003-04-01 Brookhaven Science Associates Treatment of addiction and addiction-related behavior
IL137937A0 (en) * 1999-08-27 2001-10-31 Pfizer Prod Inc A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
US6395783B1 (en) 2000-10-23 2002-05-28 Brookhaven Science Associates, Llc Treatment of PCP addiction and PCP addiction-related behavior
US6462084B1 (en) 2001-05-14 2002-10-08 Brookhaven Science Associates, Llc Treatment for obsessive-compulsive disorder (OCD) and OCD-related disorders using GVG
DE60231896D1 (en) 2001-11-05 2009-05-20 Krele Pharmaceuticals Llc COMPOSITIONS AND METHODS FOR INCREASING THE COMPLIANCE WITH THERAPIES USING ALDEHYDEDEHYDROGENASE INHIBITORS AND TREATING ALCOHOL MUSIC
JP6355921B2 (en) 2010-09-01 2018-07-11 トニックス ファーマスーティカルズ, インコーポレイテッドTONIX Pharmaceuticals, Inc. Treatment of addiction to cocaine
AU2013289922B2 (en) 2012-07-12 2016-12-15 Psyadon Pharmaceuticals, Inc. Fused benzazepines for treatment of Tourette's Syndrome
SMT202000398T1 (en) * 2013-10-18 2020-09-10 Emalex Biosciences Inc Fused benzazepines for treatment of stuttering
CN110327350B (en) * 2019-07-11 2021-02-23 温州医科大学 Application of dopamine D1 receptor antagonist SCH39166 as a drug for the treatment of ocular pathological angiogenesis
CN110833621A (en) * 2019-12-06 2020-02-25 中国医科大学 Application of dopamine receptor 1 antagonists in the preparation of drugs for the treatment of schizophrenia-like mice induced by ketamine

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5607967A (en) * 1994-10-27 1997-03-04 Merck & Co., Inc. Treatment of alzheimer's disease with 5-(tetradecyloxy)-2-furan carboxylic acid
AU3408097A (en) * 1996-06-06 1998-01-05 Ergo Research Corporation Treatment of lipid and glucose metabolism disorders with dopamine and seroto nin agonists

Also Published As

Publication number Publication date
WO1999021540B1 (en) 1999-10-28
SK5812000A3 (en) 2000-12-11
HUP0100115A2 (en) 2001-06-28
JP2001520989A (en) 2001-11-06
AR015984A1 (en) 2001-05-30
WO1999021540A3 (en) 1999-09-02
CA2308453A1 (en) 1999-05-06
AU1110099A (en) 1999-05-17
ZA989786B (en) 1999-04-28
NO20002149D0 (en) 2000-04-27
EP1043980A2 (en) 2000-10-18
PE122299A1 (en) 1999-12-04
CN1283116A (en) 2001-02-07
IL135659A0 (en) 2001-05-20
KR20010031470A (en) 2001-04-16
WO1999021540A2 (en) 1999-05-06
CO4970824A1 (en) 2000-11-07
BR9814830A (en) 2000-10-03

Similar Documents

Publication Publication Date Title
NO20002149L (en) Procedure for reducing mammalian addiction
DK0542903T3 (en) Cocaine Receptor-binding ligands
BG102668A (en) Application of ppar-alpha and prar-gamma antagonist for the treatment of syndrome x
NO971288D0 (en) Zone isolation device adapted to be placed in a borehole, and method of perforating a formation penetrated by a borehole
ID21020A (en) DETERGENT ADDITIVE COMPOSITION FOR DIESEL FUEL
NO962857D0 (en) Formation injection tool for placement in situ downhole
NO963742D0 (en) Method of stimulating hematopoiesis with hemaglobin
NO980729L (en) Process for reducing the acid content in crude oil
FI884833A7 (en) Fuel injection pipe and method for manufacturing the same
MY143582A (en) Antibodies to opgl
ATE214276T1 (en) COMPOSITIONS OF OPIOID ANTAGONISTS WITH SELECTIVE SEROTONIN UPtake INHIBITORS, FOR THE TREATMENT OF ALCOHOLISM AND ALCOHOL DEPENDENCE
FI945251A7 (en) Method for detecting disturbances in running diesel engines
IL98574A0 (en) Piperidyl-substituted indoles
GR3026655T3 (en) Sequential removal of monosaccharides from the reducing end of oligosaccharides and uses thereof.
MX9606179A (en) Agonists and antagonists of the nicotinic acetylcholine receptors of insects to control endoparasites.
DK0739354T3 (en) Preparations and Methods Using Unbound MPL Receptor to Stimulate Platelet Production
DE59610170D1 (en) Method for reducing the charge carrier concentration in order to lower the storage charge in semiconductor components by means of two implantation stages
Smith et al. Technical Brief No. 50: Sanitary Surveying
WO2000048622A3 (en) Method for inhibiting inflammatory responses
NO20006382L (en) Method of treating organophosphate poisoning
DK346387A (en) PROCEDURE FOR REDUCING THE ALKALIA CONTENT IN CEMENT CLINKS
AU7125998A (en) Method and system to locate leaks in subsurface containment structures using tracer gases
AU2910589A (en) Diagnostic method for primary biliary cirrhosis and antibodies suitable to be used in the method
KR950027711U (en) Rock wool injector
Kleingarn Structural Fire Protection Measures for Hot-Dip Galvanized Steel Structures

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application